PhaseBio Pharmaceuticals, Inc. Common Stock
PHAS
PHAS was delisted on the 2nd of November, 2022.
51 hedge funds and large institutions have $118M invested in PhaseBio Pharmaceuticals, Inc. Common Stock in 2019 Q4 according to their latest regulatory filings, with 11 funds opening new positions, 14 increasing their positions, 16 reducing their positions, and 18 closing their positions.
53% more capital invested
Capital invested by funds: $77.3M → $118M (+$41.2M)
12% less funds holding
Funds holding: 58 → 51 (-7)
13% less repeat investments, than reductions
Existing positions increased: 14 | Existing positions reduced: 16
39% less first-time investments, than exits
New positions opened: 11 | Existing positions closed: 18
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GTC
Ghost Tree Capital
New York
|
+$1.85M |
| 2 |
FCM
Farallon Capital Management
San Francisco,
California
|
+$791K |
| 3 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$718K |
| 4 |
BlackRock
New York
|
+$328K |
| 5 |
ECM
ExodusPoint Capital Management
New York
|
+$74.8K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$3.4M |
| 2 |
RSCM
Rock Springs Capital Management
Baltimore,
Maryland
|
-$1.2M |
| 3 |
CS
Candriam SCA
Strassen, Luxembourg,
Luxembourg
|
-$440K |
| 4 |
Millennium Management
New York
|
-$250K |
| 5 |
Renaissance Technologies
New York
|
-$234K |
PHAS Hedge Fund Activity: Q4 2019 in Review
51 of the 5,075 institutional investors tracked by Wall St. Rank reported a position in PhaseBio Pharmaceuticals, Inc. Common Stock (PHAS) for Q4 2019, worth a combined $118M — up 53% from $77.3M a quarter earlier.
Sellers outnumbered buyers: 18 funds closed out of PHAS and 11 opened new positions — a net loss of 7 holders — while 16 trimmed existing stakes and 14 added.
The largest buyer was Ghost Tree Capital, opening a new position worth an estimated $1.85M. The largest seller was Cormorant Asset Management, exiting entirely with an estimated $3.4M sold.
- 51 institutional investors held PhaseBio Pharmaceuticals, Inc. Common Stock (PHAS) as of Q4 2019, down from 58 in Q3 2019.
- Funds reported $118M of PhaseBio Pharmaceuticals, Inc. Common Stock stock for Q4 2019, up 53% quarter-over-quarter.
- 11 funds opened new PhaseBio Pharmaceuticals, Inc. Common Stock positions in Q4 2019 and 18 closed out, a net change of -7 holders.
- The largest PhaseBio Pharmaceuticals, Inc. Common Stock buyer in Q4 2019 was Ghost Tree Capital, an estimated $1.85M added.
- The largest PhaseBio Pharmaceuticals, Inc. Common Stock seller in Q4 2019 was Cormorant Asset Management, an estimated $3.4M sold.
Based on aggregated 13F filings for Q4 2019.